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Abstract Subclinical hyperthyroidism (sHT) was found
to be associated with elevated heart rate, blood pressure
and increased risk of extrasystoles. However, the full
clinical relevance of morphological and functional impli-
cations of sHT on the cardiovascular system is still a matter
of debate. The aim of the study was to prospectively assess
the influence of endogenous sHT on exercise capacity and
cardiac function during workout with the use of exercise
electrocardiography (ExECG) and perfusion scintigraphy.
The studied group consisted of 44 consecutively recruited
patients diagnosed with sHT. In all patients, ExECG, fol-
lowed by post-exercise myocardial perfusion imaging, was
performed. Both ExECG and scintigraphy were performed
twice—in the state of sHT and after euthyroidism was
restored. An average time period of exercise test was sig-
nificantly longer in the state of euthyroidism than in sHT.
An average oxygen consumption during exercise test was
also higher after euthyroidism was achieved when com-
pared to sHT. The end-diastolic and end-systolic volume
indexes, stroke volume index and cardiac index were sig-
nificantly larger in patients with sHT if compared values
achieved after euthyroidism restoration. Stroke volume
index was negatively correlated with TSH, and positively
with free thyroid hormones values in the state of sHT,
before euthyroidism was achieved. Cardiac index was
positively correlated with free thyroid hormones levels.
The obtained results indicate worse physical capacity in
subjects with sHT and improvement of several parameters
assessed during ExECG and perfusion scintiscan after
therapy. Observed changes might reflect the mechanism of
the deleterious effect exerted by sHT on the heart.
Keywords Subclinical hyperthyroidism  Perfusion
scintigraphy  Exercise electrocardiogram  Workout
Introduction
Subclinical hyperthyroidism (sHT) is by definition a con-
dition characterized by low or undetectable TSH concen-
tration with free thyroid hormones maintained within the
reference ranges [1]. The prevalence of sHT is estimated at
about 1 % of general population [2]. It has been demon-
strated that sHT exerts negative impact on quality of life
and increases the risk of cardiovascular mortality [3–5];
however, data on the influence of sHT on overall mortality
are inconsistent [6–9]. On the other hand, reports have
demonstrated that the negative impact of sHT on cardio-
vascular risk, which is recognized in young adults, is less
evident in elderly subjects aged 85 years or older [10]. One
of the most important parameter modified by sHT is car-
diovascular performance. Subclinical thyroid hyperfunc-
tion was found to be associated with elevated heart rate and
blood pressure as well as increased risk of both
supraventricular and ventricular extrasystoles [4, 11, 12].
What is more, sHT might also affect hemodynamics by the
negative impact on left ventricular diastolic function and
hypertrophy [13]. Although the harmful impact of overt
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hyperthyroidism on the cardiovascular system is well
documented, the clinical relevance of morphological and
functional implications of sHT is still a matter of debate [1,
4, 11, 13].
The aim of the study was to prospectively assess the
influence of endogenous sHT on exercise capacity and
cardiac function during workout with the use of electro-
cardiographic exercise treadmill test (ExECG) and perfu-
sion scintigraphy.
Subjects and methods
The studied group consisted of 44 consecutively recruited
patients (37 women and 7 men), aged from 22–65 years,
mean value 45.9 ± 11.0 diagnosed with sHT. The same
cohort of patients had already been studied in the two
previous papers of a cycle [11, 13]. The patients were
enroled to the study from a group of 1080 subjects referred
to our department because of hyperthyroidism (ICD 10—
E.05) from April of 2002 to December 2004. Patients were
diagnosed with sHT on the basis of the following labora-
tory criteria:
decreased thyroid-stimulating hormone (TSH) concen-
tration, below lower normal limit (\0.36 uIU/ml)—at
least twice, measured in a period of 6 months;
normal free thyroid hormones: free triiodothyronine—
FT3 (3.5–7.9 pmol/l) and free thyroxin—FT4
(7.64–19.7 pmol/l)—at least twice, measured in a period
of 6 months;
negative anti-thyroid autoantibodies: anti-thyroid perox-
idase (TPOAb), anti-thyroglobulin (TgAb) and anti-TSH
receptor (TRAb).
A group of patients was selected in whom sHT was due
to: toxic multinodular goitre, autonomous nodule or dif-
fused thyroid autonomy. The patients had negative history
of other diseases, including cardiovascular and metabolic
diseases or were taking no medications (i.e. betablockers).
No symptoms of cardiovascular diseases when Holter
electrocardiography and echocardiography were per-
formed. Other possible causes of sHT were excluded, i.e.
Graves’ disease, thyroiditis, pregnancy, secondary
hypothyroidism and euthyroid sick syndrome. After sHT
diagnosis, the patients were subjected to radioiodine
treatment. The dose of radioisotope was calculated with the
use of the following formula [14]:
A ¼ ð100150 lCiÞ  m
RAIU24
;
where A—activity (mCi), m—mass of hyperthyroid tissue
(g) and RAIU24—iodine intake after 24 h expressed as
decimal.
Authors assessed the volume of the hot or autonomous
thyroid nodules (visualized in thyroid scintiscan) in
millilitres during the thyroid ultrasound and assumed that
mass in grams is approximately equal to the volume in
millilitres. The mean dose of given radioiodine was
448.81 ± 209.79 MBq.
The protocol of the study was approved by the local
ethical committee and all patients gave written informed
consent to participate.
In all patients ExECG, followed by post-exercise,
myocardial perfusion imaging was performed. In all
patients, both ExECG and scintigraphy were performed
twice—in the state of sHT and after restoration of euthy-
roidism. Subclinical hyperthyroidism at the moment of the
test was confirmed to last for at least 6 months (mean
duration of about 1 year), while euthyroidism was defined
as complete normalization of TSH for at least 6 months.
The treadmill test was performed according to Bruce pro-
tocol and standards of American Heart Association (AHA)
for exercise tests [15, 16]. Patients did not take medications
and remained fasting for at least 3 h prior to the test.
During the test, blood pressure was controlled in
3-min interval, during second minute of each phase. The
period of the test was symptom limited and conducted until
patient achieved at least 85 % of maximum heart rate,
calculated with the following formula: HRmax = 220—age
(years). According to AHA, indications for preterm ter-
mination of the test appeared in none of the patients [16].
By the means of ExECG, efficiency of the cardiovas-
cular system was assessed. Oxygen consumption was
expressed in metabolic equivalents (METS). Moreover,
blood pressure, heart rate and double product, defined as
systolic blood pressure multiplied by heart rate, were
interpreted.
One minute before the end of each exercise test,
740 MBq of isonitryl methoxy-isobutyl (MIBI) labelled
with technetium-99 m (99mTc-MIBI) was given intra-
venously. Forty minutes following the ExECG a gated
perfusion scintigraphy (GSPECT) with the use of dual-
head gamma camera Varicam, Elscint, was performed.
Similar to exercise tests, GSPECT was performed twice in
each patient—on diagnosis of sHT and after euthyroidism
was achieved. Both MIBI and technetium generator were
manufactured by The Research and Development Centre
for Isotopes in S´wierk, Poland. Continuous method of
recording was used. The head of gamma camera was
rotated on elliptical orbit from right anterior oblique (RAO-
45) position to left posterior oblique (LPO-45) position.
Thirty images were obtained every 6. Recording of the
activity was carried out for 20 s on each image in a matrix
of 64 9 64. During the reconstruction, standard modes of
correction (energetics, linearity, sensitivity, centre of
rotation and radioactive decay) were adopted. Butterworth
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rear projection filter was used (order of 5, cut-off of 0.5/
cm). No absorption correction was performed. In the case
of unintentional movement of the patient, a programme for
automatic motion correction was used.
For the analysis of perfusion and dysfunction of the left
ventricle, XpertPro system was used with CEQUAL (Emory
Cedars Quantitative Analysis) software by Elscint and data
development station Quantitative Gated Spect (QGS) software
by Hermes Nuclear Diagnostics. Images of the heart have been
reconstructed in three planes orthogonal to the axis of the heart:
the vertical long axis, horizontal long axis and short axis.
Determination of the degree of perfusion disturbances in
particular segments of the left ventricle wall was performed
in a semi-quantitative way using a scale, where 0—none,
1—slight, 2—moderate and 3—considerable. None of the
subjects presented the indexes of impaired systolic perfu-
sion of the left ventricle.
Systolic and diastolic function of the left ventricle was
assessed by gating the RR interval for 8 sub-periods. For
evaluation of post-exercise systolic left ventricle function,
the following parameters were used:
End-diastolic volume—EDV (ml);
End-systolic volume—ESV (ml);
Ejection fraction of the left ventricle—EF (%);
PER (Peak Ejection Rate)—maximum left ventricular
emptying calculated as the greatest percentage change in
volume that occurs in one second from the time when
EDV (EDV%/s) is achieved;
TPER (Time to Peak Ejection Rate)—time from max-
imum diastole to the point of PER (s) and
TEDES (Time from End-diastole to End-systole)—time
from achievement of EDV to the achievement of ESV (s).
In the evaluation systolic function and perfusion of the
left ventricle, the final report was included (Fig. 1):
sectional views through the heart in the short axis (SA),
horizontal long axis (HLA) and vertical long axis (VLA)
at rest and in the phase of the maximum contraction of
the left ventricle;
perfusion polar maps (Perfusion), regional ejection
fraction (EF Regional), increase in thickness (Thicken-
ing) and motion (Motion), of the walls of the left
ventricle along with the colour scale representing the
degree of perfusion;
a three-dimensional image of the left ventricle systole
and diastole maximum at an optional projection;
a chart showing the number of counts from the left
ventricle during each time sub-period;
automatically calculated ejection fraction (EF);
automatically calculated stroke volume (SV);
end-diastolic volume (EDV) and
end-systolic volume (ESV).
The values of indices of left ventricular volume: EDVI,
ESVI and SVI calculated by the following formulas:
EDVI = EDV/BSA, ESVI = ESV/BSA and SVI = SV/
BSA (ml/m2).
The diastolic function of the left ventricle was evaluated
using the following parameters:
PFR (Peak Filling Rate)—the peak filling velocity ratio.
The PFR referred to the end-systolic volume and
presented as the highest percentage increase of the
volume in one second [ESV%/s] from the time when
ESV was achieved and
TPFR (Time to Peak Filling Rate)—the time period from
the moment when the ESV was achieved to the moment
of PFR.
The complete evaluation of patients was performed
twice—at the moment of sHT diagnosis confirmation and
6 months after transition to euthyroidism, confirmed by
complete TSH normalization.
The difference between particular parameters assessed
during exercise test in the state of sHT and euthyroidism
was analysed with the use of T-Student test for dependent
variables. The correlations between the parameters of
exercise test or perfusion scintigraphy and hormonal tests
results (both in sHT and euthyroid state) were calculated
with the use of Pearson’s test. The difference between
particular parameters assessed during perfusion scintig-
raphy before and following the therapy for subclinical
hyperthyroidism was checked with T-Student test for
dependent variables. Normality was analysed by Shapiro–
Wilk test, and the equality of variances was assessed with
the use of Levene’s test. The data were analysed statis-




The results of hormonal tests were as follows (in sHT state and
after restoration of euthyroidism, respectively): TSH
0.16 ± 0.10 mIU/L versus 1.32 ± 0.75 (p\0.005), FT4
14.16 ± 2.37 pmol/L versus 13.05 ± 1.85 and FT3
6.48 ± 0.69 pmol/L versus 5.77 ± 0.57. The interval between
all performed examinations was on average 12.5 months.
Exercise test
A mean heart rate in the state of subclinical hyperthy-
roidism and after restoration of euthyroidism was as fol-
lows: 78.4 ± 6.8 versus 76.0 ± 8.0 beats/min, p = 0.004).
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No patients presented important arrhythmia during the test.
An average time period of exercise test was significantly
longer in the state of euthyroidism than in sHT (8.21 vs.
7.17 min, t = -3.5 p = 0.001). An average oxygen con-
sumption during exercise test expressed in METS was
higher after euthyroidism was achieved if compared to sHT
(10.73 vs. 9.27, t = -4.2 p\ 0.00001), while maximum
double product was higher in sHT (27,870) and decreased
to 26,327 after euthyroidism was restored (t = 2.5
p = 0.018). The parameters measured during ExECG are
presented in Table 1. There was a significant negative
correlation between METS and FT3/FT4 coefficient before
therapy (r = -0.348, p = 0.041) as well as a significant
positive correlation between maximum double product and
FT3/FT4 coefficient (r = 0.329, p = 0.041).
Perfusion scintigraphy
The end-diastolic volume index (EDVI) was significantly
larger (45.82 ml/m2) in patients with sHT if compared to
the value 40.62 ml/m2 obtained after euthyroid state was
achieved (t = 3.2 p = 0.002). Similar observation con-
cerned end-systolic volume index (ESVI), which was
19.45 ml/m2 and dropped to 16.40 ml/m2 with the therapy
(t = 2.3 p = 0.025). Two more parameters were also
found to be higher in patients with sHT if compared to
Fig. 1 A sample test results of the ECG-gated perfusion scintigraphy
performed before the radioiodine therapy that shows no cardiological
problems. Acquisition was carried out in 40 min after injection of
740 MBq of Tc-99 m MIBI on top of the stress test carried out on a
treadmill. The column on the left depicts cross sections through the
myocardium in each sub-period of the contraction of the left ventricle.
ED (end-diastolic) means the period of maximum diastole of the left
ventricle, ES (end-systolic) means the period of maximum contraction
of the left ventricle. The top three rows in this column sections depict
the short axis of the heart. The following sections represent the
horizontal long axis and vertical long axis of the heart. In the middle
column, there are successively from the top: polar map of perfusion of
the left ventricle (Perfusion) as a percentage of the maximum uptake,
polar map of wall motion (motion) in millimetres, and a three-
dimensional image of the left ventricular cavity during the end-
diastole. In the column on the right there are: map of regional left
ventricular ejection fraction (EF Regional), polar map of the
thickening during systole and three-dimensional image of the left
ventricle during end-systolic period. In addition, the image presented
personal data and acquisition parameters. In the lower right corner,
there is a curve depicting the volume changes in the sub-periods of
heart contraction. Sep septum, LAT lateral wall
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those measured after restoration of euthyroidism: stroke vol-
ume index (SVI, 26.36 vs. 24.21 ml/m2, respectively, t = 1.9,
p = 0.042) and cardiac index (CI 2.35 vs. 2.14 ml/m2,
respectively, t = 2.0, p = 0.041). The parameters measured
during perfusion scintigraphy are presented in Table 2.
Moreover, the correlation between particular parameters
measured during perfusion scintigraphy and hormonal tests
results was assessed. Significant negative correlation was
found in sHT between SVI and TSH in patients before
therapy (r = -0.318, p = 0.041), while significant positive
correlation was found between SVI and FT3 (r = 0.347,
p = 0.008) as well as SVI and FT4 (r = 0.395,
p = 0.0005). A significant positive correlation before ther-
apy was found also for CI and FT3 (r = 0.323, p = 0.032)
as well as for CI and FT4 (r = 0.300, p = 0.048).
Discussion
The presented study constitutes the third one of a cycle in
which we demonstrate a profound influence of sHT on
cardiovascular performance by prospective assessment of
patients with endogenous sHT done before therapy and
after euthyroidism was restored, using different methods of
diagnosis [11, 13]. In our previous studies, we analysed the
results of echocardiography, 24-h ambulatory blood pres-
sure monitoring and 24-h electrocardiography. It was
demonstrated that endogenous sHT was associated with
statistically significant increase in QT dispersion, incidence
of ventricular extrasystoles, elevated nocturnal arterial
blood pressure and changes in heart rate variability [11].
Moreover, sHT was associated with increased volume of
Table 1 Values of the parameters measured during exercise ECG (ExECG) in sHT and after euthyroidism was restored
Parameter sHT Euthyroidism p
Mean Confidence interval SD Mean Confidence interval SD
-95 % ?95 % -95 % ?95 %
Exercise duration (min) 7.17 6.33 8.01 2.76 8.21 7.29 9.13 3.02 0.001
METS 9.27 8.349 10.18 3.016 10.73 9.674 11.78 3.458 <0.001
RR-max (mmHg) 171.36 164.79 177.94 21.630 166.48 160.68 172.27 19.065 0.139
Maximum double product (b*mmHg/min) 27,870.1 26,759.8 28,980.4 3652.1 26,531.1 25,462.0 27,600.3 3516.5 0.018
HRmax (b/min) 162.82 157.35 168.29 18.000 164.98 159.24 170.72 18.882 0.334
percentage of estimated HRmax (%) 93.09 90.13 96.05 9.728 95.41 92.86 97.95 8.370 0.086
Bold values indicate statistical significance (p\ 0.05)
sHT subclinical hypothyroidism, SD standard deviation, METS metabolic equivalents, RR-max maximum blood pressure, HRmax maximum
heart rate
Table 2 The results of the
parameters measured during
perfusion scintigraphy in sHT
and after euthyroidism were
restored
Parameter sHT Euthyroidism p
Mean Confidence interval SD Mean Confidence interval SD
-95 % ?95 % -95 % ?95 %
Post-exercise EF 62.35 59.99 64.71 7.67 63.77 61.35 66.19 7.87 0.102
PFR (%/s) 336.00 297.49 374.51 110.37 319.71 279.46 359.95 115.35 0.427
PER (%/s) 359.56 317.19 401.93 121.43 373.32 341.08 405.57 92.42 0.432
TPFR (ms) 517.32 477.79 556.86 113.31 545.82 510.09 581.55 102.40 0.183
TPER (ms) 198.97 160.90 237.04 109.11 176.74 150.74 202.73 74.51 0.389
TEDES (ms) 365.85 332.81 398.89 94.70 373.56 345.82 401.29 79.49 0.715
EDVI (ml/m2) 45.82 42.60 49.04 10.58 40.62 36.23 45.00 14.42 0.002
ESVI (ml/m2) 19.45 16.44 22.47 9.91 16.40 14.08 18.73 7.65 0.025
SVI (ml/m2) 26.36 23.21 29.52 10.38 24.21 20.80 27.62 11.22 0.042
CI (l/min m2) 2.35 2.06 2.63 0.95 2.14 1.83 2.45 1.05 0.041
Bold values indicate statistical significance (p\ 0.05)
sHT subclinical hypothyroidism, SD standard deviation, EF ejection fraction, PFR peak filling rate, PER
peak ejection rate, TPFR time to peak filling rate, TPER time to peak ejection rate, TEDES time from end-
diastole to end-systole, EDVI end-diastolic volume index, ESVI end-systolic volume index, SVI stroke
volume index, CI cardiac index
516 Endocrine (2016) 53:512–519
123
heart chambers and ascending aorta, increased left ventri-
cle mass and disturbed left ventricle relaxation. The
changes were reversible with restoring biochemical
euthyroidism [13]. This time, patients with sHT were
subjected to physical exercise, and cardiovascular perfor-
mance was evaluated with exercise ECG and perfusion
scintigraphy.
The use of exercise testing in cardiological diagnostics
is based on the assumption that exercise may provoke a
disclosure of some latent abnormalities in cardiovascular
system, which are undetected in examinations performed
without load. In healthy people, during physical activity,
several parameters including total oxygen consumption,
minute volume and heart rate increase to the limit of
physical capacity, defined as the maximum effort. Above
this threshold, further work is done at the expense of
anaerobic processes, and does not generate increase in
minute volume and heart rate [17]. For patients, exercise
could be limited by the onset of clinical symptoms and
electrocardiographic abnormalities. ECG testing generally
is recommended for risk assessment in patients with
ischemic cardiac disease [18]. The occurrence of ST-seg-
ment depression at a reduced workload or persisting into
recovery coupled with exertional symptoms is described to
be associated with a high risk of cardiovascular events and
mortality. In our study, ExECG was used to assess func-
tional capacity and to exclude coronary artery disease in
patients with sHT. Similarly, exercise SPECT has also
been shown to effectively assess risk of subsequent events
in patients with ischemic heart disease, with a low annu-
alized event rate of 1.6 % observed in patients with a
normal adenosine SPECT versus 10.6 % in patients with a
severely abnormal study (summed stress score more than
13).
It is assumed that an exercise at the level of 85–90 % of
maximum effort, expressed as the maximum heart rate
limit, is an adequate test to assess blood supply to the heart
muscle [16, 19]. No signs of ischaemia at this load reflect
good state of coronary circulation. In our study, an average
heart rate limit of the patients was 93 % before and 95 %
after recovering from sHT. None of the subjects demon-
strated neither clinical nor electrocardiographic character-
istics of coronary artery disease.
Biondi et al. compared the results of ExECG performed
on a bicycle ergometer in 10 patients suffering from
exogenous sHT with the results of appropriately matched
group of 10 healthy subjects [20]. The findings were con-
sistent with the results of our study.
In another study, 19 patients with exogenous sHT
underwent spirometric maximal exercise test. When the
results were compared with those obtained in an equally
large control group of healthy subjects, it turned out that
patient with sHT had significantly reduced exercise
capacity, oxygen consumption and anaerobic threshold
[21].
The metabolic equivalent (MET) is a unit of oxygen
uptake by the human body at rest. It is assumed that 1 MET
reflects an absorption of 3.5 ml O2 per 1 kg body per
minute. A maximum oxygen uptake is influenced by age,
gender, habitual physical activity, genetic factors and
finally the state of the cardiovascular system. A study
conducted at the Mayo Clinic demonstrated that the ability
to perform work expressed in metabolic equivalents
(METS) was the only variable if an effort on a treadmill is
concerned, which was related to total mortality in the
studied group [22]. Maximal values of oxygen uptake
(VO2max) are usually achieved between 15 and 30 years of
age and decreases by an average of 8–10 % per decade,
both in people leading a sedentary lifestyle, as well as in
athletes [23]. It should be noted that despite the fact that at
the time of performing repeated tests, the patients were on
average 1 year older (VO2max theoretically should have
decreased during this period by about 1 %), the recovery
from sHT resulted in a statistically significant increase in
METS by 16 % (from 9.27 to 10.73).
The so-called double product, which is achieved by
multiplying the maximum heart rate and systolic blood
pressure, allows indirect evaluation of load and consump-
tion of oxygen by the myocardium [24, 25]. ExECG studies
conducted in the phase of sHT demonstrated a significantly
greater value of the double product and at the same time
lower overall oxygen consumption (METS) as well as
shortening of exercise duration. This indicates that
endogenous sHT is characterized by a decrease in general
physical fitness and workout for patient with sHT causes
disproportionate burden to the heart. Similarly, in the work
by Biondi et al. performed on patients with exogenous
sHT, a limited exercise capacity in terms of reduced ability
to do the workout (expressed in Watts) and shortening of
the effort time were found to be associated with sHT [26].
These authors also found that the group of patients with
sHT double product was significantly higher during the
same load as compared to a control group of healthy
people.
Correlations found in our work between the ExECG
parameters and indicators of sHT activity may indicate that
a reduction in overall physical capacity and increase in the
burden on the heart in the course of endogenous sHT might
be due to disturbed ratio between the concentrations of
biologically more active triiodothyronine and less active
thyroxine (FT3/FT4).
ECG-Gated Single Photon Emission Computed
Tomography (GSPECT) is currently a valuable and widely
used technique, which allows for assessment of perfusion
and function of the left ventricle [27, 28]. In the study,
GSPECT was used in order to assess the hemodynamic
Endocrine (2016) 53:512–519 517
123
indices and to exclude coronary artery disease in the
studied group of patients with sHT. In a semi-quantitative
assessment during GSPECT, none of the patients, either
before or after recovering from sHT, demonstrated
impairment of myocardial perfusion during contraction,
which confirmed earlier exclusion of coronary artery dis-
ease. In quantitative evaluation during GSPECT, statisti-
cally significant differences between designated
parameters, assessed during and after recovering from sHT,
were noted.
Our paper is the first in the world literature to evaluate
the results of GSPECT examination conducted in patients
with endogenous sHT. However, there were two studies in
patients with exogenous sHT, in which for the evaluation
of cardiac function, a labelled radioisotope was used.
Biondi et al. performed a study with a control group, in
which a radionuclide angioscintigraphy was performed at
rest and during submaximal exercise test in 10 patients
with sHT [20]. It was concluded that sHT was associated
with a slight non-significant increase in ejection fraction,
end-diastolic volume and peak ejection rate as well as
statistically significant decrease in peak filling rate.
In another paper, 11 patients with exogenous sHT
demonstrated a higher heart rate and not significantly
increased ejection fraction [29]. Faber et al. compared the
hemodynamic measurements performed with the use of
impedance cardiography in a group of 6 women before and
after recovery from endogenous sHT following radioiodine
therapy [30]. After restoration of euthyroidism, 19 %
reduction (p\ 0.05) in cardiac output and cardiac index as
well as 30 % increase in systemic vascular resistance, were
observed. In this small group of patients with sHT, no
correlation was found between concentrations of hormones
and haemodynamic parameters. However, after increasing
the sample size, the negative correlation between TSH and
the minute cardiac output and an index of aortic compli-
ance as well as positive correlation between TSH and
systemic vascular resistance were noted. Moreover, a
positive correlation was found between FT3 and a minute
cardiac output and an index of aortic compliance as well as
negative correlation between FT3 and mean arterial pres-
sure and systemic vascular resistance. In our study, no
significant differences in parameters describing left ven-
tricle filling and emptying before and after therapy were
noted. It has been shown, however, that this group of
patients is characterized by the increase in both end-dias-
tolic and end-systolic volume. Larger difference between
these parameters (EDV—ESV) during sHT results in
increased stroke volume and cardiac index. Correlations
suggest an influence of relative excess concentration of
thyroid hormones (also expressed only as TSH suppres-
sion) on stroke volume and cardiac index value.
To conclude, the paper constitutes, the first, to
prospectively assess the workout performance, and the
influence of sHT on the cardiovascular system exercise
tolerance in patients with endogenous sHT and after
euthyroidism was restored. The obtained results indicate
worse physical capacity in subjects with sHT and
improvement of several parameters assessed during exer-
cise ECG and perfusion scintiscan after therapy. Observed
changes might reflect the mechanism of the deleterious
effect exerted by sHT on the heart.
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